Xeris Biopharma Reports Strong Q4 Revenue Growth Amid Pipeline Advancements

Xeris Biopharma reported Q4 revenue of $68.2 million, up 37% compared to the same period in the prior year, reflecting sustained demand for its proprietary formulations of glucagon and insulin therapies. The growth was primarily fueled by increased U.S. prescription volume for Gvoke HypoCharger and Xeris' ongoing commercial expansion in pediatric diabetes markets. The company also highlighted progress across its pipeline, including the initiation of a Phase 3 trial for XR-311, a novel, rapid-acting insulin analog designed for improved glucose control. Additionally, two Phase 2 trials for XR-1211, a non-injectable glucagon alternative, are underway, with top-line data expected in late 2026. These developments underscore Xeris’ dual focus on near-term revenue generation and long-term innovation in diabetes management. Xers’ stock (XERS) reacted positively to the earnings, trading up 8.3% in after-hours trading. The stock’s performance aligns with broader healthcare sector momentum, as the SPDR Health Care ETF (XLV) rose 1.2% and the iShares U.S. Healthcare ETF (IHI) gained 1.5% on the same day. The results suggest growing investor confidence in biotech firms with diversified product pipelines and strong commercial traction. Xeris emphasized continued investment in manufacturing scalability and regulatory strategy, including submissions for additional indications in the U.S. and Europe. The company remains on track to achieve profitability in 2027, supported by a growing revenue base and disciplined cost management.